Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 5Withdrawn 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 26Prostatic Neoplasms 22Stomach Neoplasms 12Squamous Cell Carcinoma of Head and Neck 12Lung Neoplasms 11Neoplasms 10Urinary Bladder Neoplasms 8Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 7Carcinoma, Squamous Cell 6Non-Muscle Invasive Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Carcinoma, Transitional Cell 5Adenocarcinoma 5Oropharyngeal Neoplasms 4Sarcoma 3Prostatic Neoplasms, Castration-Resistant 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Vaccinia 2Recurrence 2Peritoneal Neoplasms 2Metastatic Castration-Resistant Prostate Cancer 2Melanoma 2

Interventions

Specimen Handling 4Gemcitabine 3Doxorubicin 3liposomal doxorubicin 2Trabectedin 2Magnetic Resonance Spectroscopy 2Dacarbazine 2Biopsy 2toripalimab 1regorafenib 1peposertib 1cemiplimab 1anlotinib 1abemaciclib 1X-Rays 1Tretinoin 1Tissue Banks 1Tablets 1Surgical Procedures, Operative 1Standard of Care 1Rosuvastatin Calcium 1Radiotherapy 1Quality of Life 1Nivolumab 1Neoadjuvant Therapy 1Midazolam 1Injections 1Immunoglobulin G 1Ifosfamide 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leiomyosarcoma × Docetaxel × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡